AMEX:BDR

Stock Analysis Report

Blonder Tongue Laboratories

Executive Summary

Blonder Tongue Laboratories, Inc., a technology-development and manufacturing company, provides television signal encoding, transcoding, digital transport, and broadband product solutions in the United States.

Snowflake

Fundamentals

Adequate balance sheet and fair value.

Risks

  • Blonder Tongue Laboratories has significant price volatility in the past 3 months.
  • Blonder Tongue Laboratories is not covered by any analysts.

Similar Companies

Share Price & News

How has Blonder Tongue Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-24.4%

AMEX:BDR

3.4%

US Communications

2.1%

US Market


1 Year Return

-49.9%

AMEX:BDR

-1.9%

US Communications

-0.04%

US Market

BDR underperformed the Communications industry which returned -0.3% over the past year.

BDR underperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

BDRIndustryMarket
7 Day-24.4%3.4%2.1%
30 Day-28.2%-14.6%-3.2%
90 Day-29.1%-9.1%2.8%
1 Year-49.9%-49.9%0.2%-1.9%2.2%-0.04%
3 Year13.3%13.3%52.1%42.4%41.5%32.3%
5 Year-59.8%-59.8%81.2%62.6%55.0%37.8%

Price Volatility Vs. Market

How volatile is Blonder Tongue Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Blonder Tongue Laboratories undervalued based on future cash flows and its price relative to the stock market?

1.83x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Blonder Tongue Laboratories to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Blonder Tongue Laboratories to establish if it is available at substantial discount.


Price Based on Earnings

Blonder Tongue Laboratories is good value based on earnings compared to the US Communications industry average.

Blonder Tongue Laboratories is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Blonder Tongue Laboratories, we can't assess if its growth is good value.


Price Based on Value of Assets

Blonder Tongue Laboratories is good value based on assets compared to the US Communications industry average.


Next Steps

Future Growth

How is Blonder Tongue Laboratories expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.1%

Forecasted Tech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Blonder Tongue Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Blonder Tongue Laboratories performed over the past 5 years?

44.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Blonder Tongue Laboratories has delivered over 20% year on year earnings growth in the past 5 years.

Blonder Tongue Laboratories has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Blonder Tongue Laboratories has become profitable in the last year making it difficult to compare the US Communications industry average.


Return on Equity

Blonder Tongue Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Blonder Tongue Laboratories used its assets more efficiently than the US Communications industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if Blonder Tongue Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Blonder Tongue Laboratories's financial position?


Financial Position Analysis

Blonder Tongue Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Blonder Tongue Laboratories's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Blonder Tongue Laboratories's level of debt (0.4%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (40.6% vs 0.4% today).

Operating cash flow is negative therefore debt is not well covered.

Unable to confirm if the interest payments on Blonder Tongue Laboratories's debt are well covered by earnings due to lack of past financial data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 250.9x debt.


Next Steps

Dividend

What is Blonder Tongue Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Blonder Tongue Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Blonder Tongue Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Blonder Tongue Laboratories has not reported any payouts.

Unable to verify if Blonder Tongue Laboratories's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Blonder Tongue Laboratories has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Blonder Tongue Laboratories's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Bob Pallé (73yo)

4.3yrs

Tenure

US$170,090

Compensation

Mr. Robert J. Pallé, Jr., also known as Bob, has been Chief Executive Officer of Blonder Tongue Laboratories Inc since May 19, 2015. Mr. Pallé served as President at Blonder Tongue Laboratories, Inc. since ...


CEO Compensation Analysis

Bob's remuneration is lower than average for companies of similar size in United States of America.

Bob's compensation has increased in line with Blonder Tongue Laboratories recently becoming profitable.


Management Age and Tenure

4.3yrs

Average Tenure

54yo

Average Age

The tenure for the Blonder Tongue Laboratories management team is about average.


Board Age and Tenure

9.7yrs

Average Tenure

67yo

Average Age

The tenure for the Blonder Tongue Laboratories board of directors is about average.


Insider Trading

Blonder Tongue Laboratories individual insiders have sold more shares than they have bought in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

SellUS$5,02619 Jun 19
James Williams
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,127
Max PriceUS$0.99
SellUS$10,41112 Jun 19
James Williams
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,000
Max PriceUS$1.05
BuyUS$4,80131 May 19
Ronald Alterio
EntityIndividual
Role
Chief Technology Officer
VP of Engineering & CTO
Shares5,000
Max PriceUS$0.96
SellUS$4,85029 May 19
James Williams
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$0.97
SellUS$4,75028 May 19
James Williams
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$0.95
SellUS$4,60021 May 19
James Williams
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$0.92
SellUS$4,81021 May 19
James Williams
EntityIndividual
Role
Member of the Board of Directors
Director
Shares5,000
Max PriceUS$0.96
BuyUS$76420 Dec 18
Edward Grauch
EntityIndividual
Role
President
President & COO
Shares637
Max PriceUS$1.20
BuyUS$11,48419 Dec 18
Edward Grauch
EntityIndividual
Role
President
President & COO
Shares9,261
Max PriceUS$1.24
SellUS$7,55319 Dec 18
Jeffrey Smith
EntityIndividual
Role
Head of Sales
Vice President of Sales
Shares6,649
Max PriceUS$1.14
BuyUS$10,47718 Dec 18
Ronald Alterio
EntityIndividual
Role
Chief Technology Officer
VP of Engineering & CTO
Shares8,387
Max PriceUS$1.25
BuyUS$18,16514 Dec 18
Edward Grauch
EntityIndividual
Role
President
President & COO
Shares15,100
Max PriceUS$1.20
BuyUS$1,73612 Dec 18
Edward Grauch
EntityIndividual
Role
President
President & COO
Shares1,527
Max PriceUS$1.14
BuyUS$1,08411 Dec 18
Edward Grauch
EntityIndividual
Role
President
President & COO
Shares943
Max PriceUS$1.15
BuyUS$2,88411 Dec 18
Edward Grauch
EntityIndividual
Role
President
President & COO
Shares2,508
Max PriceUS$1.15
SellUS$35,01606 Dec 18
Jeffrey Smith
EntityIndividual
Role
Head of Sales
Vice President of Sales
Shares31,666
Max PriceUS$1.11
BuyUS$23,06806 Dec 18
Edward Grauch
EntityIndividual
Role
President
President & COO
Shares20,239
Max PriceUS$1.14
BuyUS$2,35230 Nov 18
Gary Scharmett
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares2,010
Max PriceUS$1.17
BuyUS$12,40030 Nov 18
Gary Scharmett
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$1.24
BuyUS$34,58430 Nov 18
Steven Shea
EntityIndividual
Role
Chairman of the Board
Chairman
Shares30,000
Max PriceUS$1.15
BuyUS$2,43930 Nov 18
Edward Grauch
EntityIndividual
Role
President
President & COO
Shares2,217
Max PriceUS$1.10
BuyUS$30,09328 Nov 18
Edward Grauch
EntityIndividual
Role
President
President & COO
Shares27,568
Max PriceUS$1.09

Ownership Breakdown


Management Team

  • Bob Pallé (73yo)

    CEO & Director

    • Tenure: 4.3yrs
    • Compensation: US$170.09k
  • Eric Skolnik (54yo)

    Senior VP

    • Tenure: 18.3yrs
    • Compensation: US$228.36k
  • Ted Grauch (53yo)

    President & COO

    • Tenure: 0.2yrs
  • Jeff Smith (55yo)

    Vice President of Sales

    • Tenure: 8.3yrs
    • Compensation: US$251.05k
  • Ron Alterio (49yo)

    VP of Engineering & CTO

    • Tenure: 1.1yrs

Board Members

  • Anthony Bruno (78yo)

    Independent Director

    • Tenure: 11.5yrs
    • Compensation: US$60.32k
  • Bob Pallé (73yo)

    CEO & Director

    • Tenure: 4.3yrs
    • Compensation: US$170.09k
  • Gary Scharmett (63yo)

    Independent Director

    • Tenure: 21.7yrs
    • Compensation: US$56.15k
  • James Williams (61yo)

    Director

    • Tenure: 25.9yrs
    • Compensation: US$54.75k
  • James Williams (87yo)

    Director

    • Tenure: 4.5yrs
    • Compensation: US$51.55k
  • Steve Necessary (62yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$54.84k
  • Steve Shea (60yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$84.85k
  • Charles Dietz (71yo)

    Independent Director

    • Tenure: 7.9yrs
    • Compensation: US$59.15k

Company Information

Blonder Tongue Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Blonder Tongue Laboratories, Inc.
  • Ticker: BDR
  • Exchange: AMEX
  • Founded: 1950
  • Industry: Communications Equipment
  • Sector: Tech
  • Market Cap: US$6.545m
  • Shares outstanding: 9.62m
  • Website: https://www.blondertongue.com

Number of Employees


Location

  • Blonder Tongue Laboratories, Inc.
  • One Jake Brown Road
  • Old Bridge
  • New Jersey
  • 8857
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BDRAMEX (NYSE MKT LLC)YesCommon StockUSUSDDec 1995

Biography

Blonder Tongue Laboratories, Inc., a technology-development and manufacturing company, provides television signal encoding, transcoding, digital transport, and broadband product solutions in the United Sta ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 23:33
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.